Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$14.13 USD
-0.03 (-0.21%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.14 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Eton Pharmaceuticals, Inc.'s return on equity, or ROE, is -3.15% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that ETON has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ETON 14.13 -0.03(-0.21%)
Will ETON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ETON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETON
Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why
ETON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates
Other News for ETON
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, ...
BlackRock, Inc. Expands Stake in Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc (ETON) Shares Up 8.03% on Jul 18
Eton Pharma Near Term Catalysts Vanish
Eton Pharmaceuticals management to meet with B. Riley